Xu Zhu

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Hai‐Dong Zhu, Hai-Liang Li, Mingsheng Huang et al. · Signal Transduction and Targeted Therapy · 2023 · 262 citations · Full text

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Shukui Qin, Li Qiu, Shanzhi Gu et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 243 citations

Hepatology, Medicine, Pathology +6

Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial

Kanglian Zheng, Xu Zhu, Shijie Fu et al. · Radiology · 2022 · 140 citations

Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma

Baojiang Liu, Song Gao, Xu Zhu et al. · Immunotherapy · 2021 · 73 citations · Full text

Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis

Jungang Hu, Quan Bao, Guang Cao et al. · CardioVascular and Interventional Radiology · 2020 · 68 citations

Hepatology, Medicine, Liver Cancer +8